Bi-functional co-polymer use for ophthalmic and other topical and local applications
The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided.
1. A method for prolonging the stability of an ocular surface tear film of a subject, comprising contacting said ocular surface of said subject with a composition comprising a graft copolymer having a positively charged backbone and hydrophilic water soluble side chains, wherein said graft copolymer is PLL-g-PEG in an amount and for a duration so as to prolong the stability of said tear film of said subject.
2. The method of claim 1 , wherein said graft copolymer creates a covalent adhesion between said graft copolymer and said ocular surface.
3. The method of claim 1 , wherein said graft copolymer comprises 0.001 to 40% of said composition.
4. The method of claim 1 , wherein said composition further comprises a second polymer.
5. The method of claim 1 , wherein said composition further comprises one or more of a surfactant, a preservative, and a pharmaceutical ingredient selected from the group consisting of: a demulcent, an emollient, sodium chloride and a vasoconstrictor.
6. The method of claim 1 , wherein said composition is contacted topically to an eye of a subject by an eye drop or an eye care solution.
7. The method of claim 1 , wherein said composition is topically administered to an eye of a subject to treat dry eye, ophthalmic irritation, or corneal epithelial disease.
8. The method of claim 7 , further comprising administering to said eye a second, different eye drop.
9. The method of claim 5 , wherein said vasoconstrictor is selected from the group consisting of Ephedrine hydrochloride, Naphazoline hydrochloride, Phenylephrine hydrochloride and Tetrahydrozoline hydrochloride.
10. The method of claim 5 , wherein said emollient is selected from the group consisting of Lanolin, mineral oil, paraffin, petrolatum, white ointment, white petrolatum, white wax and yellow wax.
11. The method of claim 1 , wherein prolonging said stability of an ocular surface tear film of a subject provides prolonged ocular comfort to said subject.
12. The method of claim 1 , wherein said composition is in a volume sufficient for instillation in the eye, and wherein said graft copolymer is at a concentration ranging from 0.1 to 3 wt %.
13. The method of claim 1 , wherein said composition has a viscosity of less than 20 cP.
14. The method of claim 1 , wherein said composition has a viscosity ranging from 1 cP up to and including 100 cP.
15. The method of claim 1 , wherein said composition has a viscosity ranging from 2 cP up to and including 30 cP.
16. The method of claim 1 , wherein said composition further comprises a poly(ethylene oxide)-poly(propylene oxide) block co-polymer surfactant.
17. A method for prolonging the stability of an ocular surface tear film of a subject, comprising contacting an ocular surface of said subject with a composition comprising a graft copolymer having a positively charged backbone and hydrophilic water soluble side chains, wherein said graft copolymer is PLL-g-PEG in an amount and for a duration so as to prolong the stability of said tear film of said subject, wherein said prolonging is measured using tear film break up time (TFBUT).
18. The method of claim 17 , wherein the stability of said tear film of said subject is maintained for up to two hours.
19. The method of claim 17 , wherein said tear film break up time (TFBUT) is measured by a methodology selected from the group consisting of:
(a) measuring non-invasive tear film break up time;
(b) using Tearscope™, a non-invasive lighting system and slit lamp biomicroscope observation system comprising a source of diffuse light;
(c) assessing tear film reflectance of light and aberrations;
(d) using wavescan assessments;
(e) using blink rates; and
(f) measuring tear film break up time with fluorescein instilled in the eye.
20. The method of claim 17 , wherein prolonging the stability of said tear film of said subject provides treatment for dry eye.
21. The method of claim 17 , wherein prolonging the stability of said tear film of said subject provides for one or more selected from the group consisting of: treatment of ophthalmic discomfort, prevention of infection, adhesion of bacteria, adhesion of viruses, adhesion of proteins, adhesion of toxins and adhesion of antigens.
22. The method of claim 17 , wherein said composition further comprises an active agent for treating ophthalmic disease.
23. The method of claim 22 , wherein said active agent is selected from the group consisting of an antibiotic, acetazolamide, antazoline, aspirin, atropine, azelastine, bacitracin, betaxolol, bimatoprost, a botanical drug, lutein, lycopene brimonodine, brinzolamide, carbachol, carteolol, ciprofloxacin, ofloxacin, cromalyn, cyclosporine, a cyclosporine pro-drug, a cyclosporine derivative, an immunomodulators, dapiprazole, dexamethasone, diclofenac, dipivifren, dorzolamide, epinephrine, erythromycin, fluoromethalone, flurbiprofen, gentamycin, a glaucoma medication, gramicidin, homatropine, hydrocortisone, hyoscine, keterolac, ibuprofen, ketotifen, latanaprost, levobunolol, levocabastine, levofloxin, lotepprednol, medrysone, methazolamide, metipranolol, naphazoline, natamycin, nedocromil, neomycin, neuroprotective agents, nonsteroidal anti-inflammatory agents, nepafanec, norfloxacin, ofloxacin olopatadine, oxymetazoline, pemirolast, pheniramine, phenylephrine, pilocarpine, povidone, prednisolone, proparacaine, scopolamine, tetracaine, steroids, sulfacetamide, tetrahydrozoline, hypertonic tears, timolal, tobramycin, travaprost, trifluridine, trimethiprim, tropicamide, unoprostone and zinc.
24. The method of claim 23 , wherein said antibiotic is selected from the group consisting of fluoroquinolones, vancomycin, cephalosporin, gentamycin, erythromycin, azithromycin, sulfa drugs, bacitracin, gatifloxacin, levofloxin, moxifloxacin and ofloxacin.
25. The method of claim 24 , wherein said glaucoma medication is selected from the group consisting of a prostaglandin, a carbonic anhydrase inhibitor, an epinephrine agonist, an alpha-agonist, and a beta-blocker.